Tirzepatide and unilateral Graves' disease

A case report published on 30 August 2026 in Case Reports in Endocrinology describes a 59-year-old woman with type 2 diabetes who developed thyrotoxicosis confined to a single thyroid lobe while receiving tirzepatide^[1]. The imaging pattern, elevated free thyroid hormones, suppressed TSH, and positive autoantibodies with technetium-99m uptake restricted to the right lobe, was consistent with unilateral Graves' disease. The authors note that a causal relationship between tirzepatide and the onset of Graves' disease cannot be established from a single case, but flag the finding as worth monitoring given the drug's expanding use in diabetes and obesity.

What the case showed

The patient had been treated with tirzepatide for type 2 diabetes when she presented with symptoms of hyperthyroidism. Laboratory findings showed suppressed thyroid-stimulating hormone (TSH), elevated free thyroxine and free triiodothyronine, and positive thyroid-stimulating immunoglobulins^[1]. A technetium-99m thyroid scan found that the pathological uptake was confined to the right lobe only, a pattern the authors describe as unilateral Graves' disease, which is an unusual presentation. Most Graves' disease cases involve diffuse bilateral thyroid involvement.

The patient improved following initiation of antithyroid medication. The report does not describe permanent discontinuation of tirzepatide as a required step for resolution, though the authors recommend clinical vigilance for thyroid dysfunction in patients on this drug class.

Why unilateral Graves' disease is unusual

Graves' disease is an autoimmune condition in which thyroid-stimulating immunoglobulins bind and activate the TSH receptor, prompting excess thyroid hormone production. Classically the process affects both lobes. The unilateral pattern documented here adds a layer of diagnostic complexity: a focal uptake pattern on thyroid scintigraphy can mimic a toxic nodule, and distinguishing the two requires careful antibody testing alongside imaging. The authors relied on the positive TSI result to confirm Graves' disease as the mechanism rather than a functioning nodule.

The broader tirzepatide and thyroid picture

The tirzepatide prescribing label carries a boxed warning about a risk of medullary thyroid carcinoma (MTC) and is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). That warning concerns C-cell tumours observed in rodent studies and is not about autoimmune hyperthyroidism^[2]. The current case falls into a separate category.

A retrospective analysis published in Clinical Obesity in June 2026 examined 527 patients treated with tirzepatide and found that 28 (5.3%) developed or had progression of thyroid disease during the observation period^[3]. Graves' disease was among the diagnoses documented in that cohort. The study cannot determine causality either, but it signals that thyroid monitoring may be warranted in some patient groups receiving the drug.

Separately, a May 2025 case report in Cureus described a 32-year-old woman without prior thyroid disease who developed painless biphasic thyroiditis two months into tirzepatide therapy^[4]. That case differed from the current one in that thyroid autoantibodies were negative and the condition resolved after discontinuation, suggesting a drug-triggered destructive process rather than an autoimmune mechanism.

A 2025 review in Cureus noted that GLP-1 receptor agonists exert immunomodulatory effects, including suppression of pro-inflammatory cytokines and effects on regulatory T-cell function^[5]. Whether those immune effects can contribute to the onset of autoimmune thyroid disease in susceptible patients is unresolved. The mechanistic path from GLP-1 or GIP receptor activation to thyroid autoimmunity has not been established in human studies.

What this is not

One case report does not establish a drug-induced cause. Graves' disease is common in the general population, particularly in women in their middle and later decades, and temporal association with a drug does not confirm attribution. The 59-year-old patient in this report fits the demographic profile for de novo Graves' disease independent of any medication. The authors' conclusion is measured: the association merits attention and surveillance, not a clinical alarm.

The existing tirzepatide prescribing label does not list Graves' disease or autoimmune hyperthyroidism as known adverse effects. Post-marketing pharmacovigilance databases may accumulate more reports over time, but as of this writing there is no regulatory signal driving a label change on this point.

What to watch and where to find more

Clinicians managing patients on tirzepatide who present with symptoms of hyperthyroidism, palpitations, heat intolerance, or unexplained weight loss, should include thyroid function tests and autoantibody panels in the workup. The differential in a patient on a GLP-1 or GIP agonist now includes both the class-specific boxed warning (C-cell tumours, monitored via calcitonin) and the emerging autoimmune thyroid signals in the case literature. Both investigations are distinct.

Patients should discuss any new symptoms with their prescribing clinician rather than adjusting or stopping medication independently. The benefit-risk profile of tirzepatide for diabetes management rests on a substantial clinical programme and is not overturned by a single case report. For country-specific regulatory and access information on tirzepatide, see the regulation pages linked from the peptide hub.